Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Dec 04, 2022 1:59pm
450 Views
Post# 35149618

The week ahead….min 2 announcements…more?

The week ahead….min 2 announcements…more?

So, we are starting a new week, in a new month. Last quarter of the year.
Three yrs ago we had a price surge from near $1 to a peak of near $6. 

That was driven by a few things.
Expected/ speculation Aware-1, results 
mangement using year end stock options & purchasing shares.
a short squeeze, 
essentially causing a perfect storm for an upward spiral.
Last week, we saw a brief 20%-25% spike.
back Dec 2019, There were multiple daily spikes of 30%- 50%.
hence $1 to $6 very quickly.
Move to today:
Short % is very low. Any squeeze would be negligible.
The aware-1 , data story still lives & expected to be part of this weeks news.
The pancreatic cancer results alongside Roche are awesome , more to come with that.
With Aware-1, more or less done.now leaving the Bracelet results as a possible time lag to registration.
Bracelet results are promised Q1/ H1 of 2023.
A.N. Will be reporting this week. THAT information will set the stage for phase 3 trial parameters.
Since Dec 2019, Onc has started additional trials/ collaborations with Incyte & Merck.
The Car-t , results were presented too long ago & a partnership ( car-t), is long over due.
We had partnership speculation back in 2019. 

Now multiple partnership options.....Car-t, MBc, panc & even mutiple melanoma.
talks of complete buyout? 

The buyout option could happen anytime, any day.
Could be this week, next month or 5 years from now.
Point is, unless we are in the Onc board room, We do not know for sure.
it has been stated by Onc management " we are in discussions with multiple potential partners,for multiple Pela uses".
Partnership options? The bracelet trial is the most contractual. Pfizer/Onc does have in place an agreement giving Pfizer a 90 day exclusivity of the data to pen a deal.
The others ? Same potentials as a buyout.
Roche for example could come with a partnership offer tomorrow for the Panc cancer, based in FDA fast track & the over the top resUlts.
Or"........They could wait 3 months to watch the data mature.
Many many options & possibilities.
This week ( that we know of), There will be 2 announcements. Both on MBc progress. 
both will be good news.The symposium is attended by 51% people outside of USA.
 

Now;
Point to my long jabberwalky , ONC is worth much much more than it is presently trading at.
How much & when? Depends on all of the above variables.
Myself ? I " speculate" Huge gains between now & end of March.
There will be spikes & valleys along the way.
Share price? Onc has traded since 1998 , from ..75ps to $160ps.( CDN$)
Pick a number! 

The Panc cancer results alone if Onc did not have a long history, should be trading near $10ps.
analysts have an average rating of near $8 ( usd), all with caveat to modify on further update.
Have a great week all.
Wishing everyone great health & happiness in the coming festive season.
PS , I do have Share price expectations, but I won't post as even my number changes based on all of the above notations.
I will say...." much more than now"
 






 

<< Previous
Bullboard Posts
Next >>